FST and prostate cancer: Despite high serum levels of FST associating with poor prognosis in hepatocellular carcinoma [52, 53] and high tumour FST also representing a negative prognostic factor in lung, ovarian and gastric cancer [49], survival data from the TCGA database indicates that high tumoural expression of FST does not correlate with altered disease‐free survival of prostate cancer patients (Fig. S16).